Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesAcute Rejection and Humoral Sensitization in Lung Transplant Recipients
Proceedings of the American Thoracic Society, 01/14/09
Martinu T et al. - Treatment options for cellular rejection include high-dose methylprednisolone, antithymocyte globulin, or alemtuzumab. Treatment options for humoral rejection include intravenous immunoglobulin, plasmapheresis, or rituximab. A greater mechanistic understanding of cellular and humoral forms of rejection and their role in the pathogenesis of BOS is critical in developing therapies that extend long-term survival after lung transplantation.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Tadalafil for the treatment of pulmonary arterial hypertension
Expert Opinion in Pharmacotherapy, 12/14/09
Bosentan for chronic thromboembolic pulmonary hypertension
Expert Review of Cardiovascular Therapy , 12/14/09
Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children
Pediatric Allergy and Immunology, 12/14/09
Today in Transplantation...keeping you current
Receive free subspecialty "5-minute updates" via email
Lung transplantation for pediatric pulmonary hypertension
Progress in Pediatric Cardiology, 12/11/09
Survival After Bilateral Versus Single-Lung Transplantation for Idiopathic Pulmonary Fibrosis
Annals of Internal Medicine, 12/03/09
Lung Allocation Score Predicts Survival in Lung Transplantation Patients With Pulmonary Fibrosis
Annals of Thoracic Surgery, 11/24/09
Sponsor
Article Search
Sponsor
Sponsor